

**NSABP Protocol B-31: Characteristics of Patients for Whom  
Pathology Material is Available for Study as of September 30, 2009**

	AC->T		AC->TH		All	
	No.	(%)	No.	(%)	No.	(%)
<b>Age at Randomization</b>						
≤39	140	(15.6)	134	(15.2)	274	(15.4)
40-49	311	(34.7)	306	(34.6)	617	(34.7)
50-59	301	(33.6)	295	(33.4)	596	(33.5)
≥60	144	(16.1)	149	(16.8)	293	(16.4)
<b>Number of Positive Nodes</b>						
1-3	514	(57.4)	505	(57.1)	1019	(57.3)
4-9	258	(28.8)	257	(29.1)	515	(28.9)
10+	124	(13.8)	122	(13.8)	246	(13.8)
<b>Estrogen Receptor</b>						
Negative	415	(46.3)	418	(47.3)	833	(46.8)
Positive	480	(53.6)	465	(52.6)	945	(53.1)
Unknown	1	(0.1)	1	(0.1)	2	(0.1)
<b>Progesterone Receptor</b>						
Negative	515	(57.5)	533	(60.3)	1048	(58.9)
Positive	378	(42.2)	349	(39.5)	727	(40.8)
Unknown	3	(0.3)	2	(0.2)	5	(0.3)
<b>Pathological Tumor Size (cm)</b>						
≤2.0	360	(40.2)	327	(37.0)	687	(38.6)
2.1-4.0	398	(44.4)	412	(46.6)	810	(45.5)
≥4.1	136	(15.2)	142	(16.1)	278	(15.6)
Unknown	2	(0.2)	3	(0.3)	5	(0.3)
<b>Tumor Grade</b>						
Good	23	(2.6)	21	(2.4)	44	(2.5)
Intermediate	269	(30.0)	239	(27.0)	508	(28.5)
Poor	597	(66.6)	616	(69.7)	1213	(68.2)
Unknown	7	(0.8)	8	(0.9)	15	(0.8)
<b>Assigned Hormonal Therapy</b>						
None	384	(42.9)	385	(43.6)	769	(43.2)
Tamoxifen or aromatase inhibitor	512	(57.1)	499	(56.4)	1011	(56.8)
<b>Intended Paclitaxel Schedule</b>						
Q 3 week	777	(86.7)	771	(87.2)	1548	(87.0)
Weekly	119	(13.3)	113	(12.8)	232	(13.0)
<b>Disease Free Survival</b>						
Event free	597	(66.6)	709	(80.2)	1306	(73.4)
Experienced an event	299	(33.4)	175	(19.8)	474	(26.6)
Total Person Months of Follow-up for Events	53,150.7		60,594.7		113,745.4	
<b>Overall Survival</b>						
Alive	721	(80.5)	781	(88.4)	1502	(84.4)
Dead	175	(19.5)	103	(11.6)	278	(15.6)
Total Person Months of Follow-up for Deaths	61,464.3		64,576.8		126,041.1	
<b>All</b>	896	(100.0)	884	(100.0)	1780	(100.0)